1Raginster JY, Felsenberg D, Pavo I, et al. Effect of raloxifene combined with monofluoropbospbate as compared with monofluoropbospbate alone in postmenopausal women with low bone mass: a randomized, controlled trial[J]. Osteoporos Int, 2003, 14:741-749. 被引量：1
2Morabito N, Gaudio A,Lasco A,et al. Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis [J]. Osteoporos Int , 2003 , 14:500-506. 被引量：1
3Elaena Q, Helen K. Teriparatide: A Review [J] . clinical thearpeutics. 2004, 26(6) : 841-854. 被引量：1
4Chuengsamarn S, Suwanwalaikorn S. Comparing the effect of short term post meal and bedtime calcium supplementation on the C-terminal telopeptide crosslinks and PTH levels in postmenopausal osteopenic women [J]. J Med Assoc Thai, 2005, 88(1) :S12-S20. 被引量：1
5Carmen G, Luis-Emilio G. Combination of anabolic and antiresorptive agents for the treatment of osteoporosis [J]. Maturitas, 2006, 54: 47-54. 被引量：1
6Herwitz MJ, Tedesco MB,Gundberg C, et al. ShortTerm, High-Dose Parathyroid Hormene-Related Pro- tein as a Skeletal Anabolic Agent for the Treatment of Postmenopausal Osteoporosis [J]. J Clin Endocrinol Metab, 2003, 88:569-575. 被引量：1
7Edith B, Anne C, Frederic S, et al. Dual effect of strontium ranelate:Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro [J]. Bone, 2007, 8, 43. 被引量：1
8Naibedya C, Stephen JQ, Olga K, et al. The calciumsensing receptor (CAR) is involved in strontium ranelate-induced osteoblast proliferation [J]. Bioche pharmacol, 2007,74: 438-447. 被引量：1
9Tsifidis E, Gamie Z,Conaghan PG,et al. Biological options to enhance pefiprosthetic bone mass. [J] Int J Care Injured, 2007, 38: 704-713. 被引量：1
10Landin-Wilhelm-sen K,Nilsson A,Bosneus I, et al. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial[J]. J Bone Miner Res,2003 ,18:393-405. 被引量：1
